(119) first reported that a 36-year-old patient with SLE who received human IL-2 recombinant (aldesleukin) 1.5 or 3.0 million IU subcutaneous injections daily for five days can improve arthritis and the increase of CD25+FoxP3+CD127lo Treg cells. This evidence concerns the gene FOXP3 and systemic lupus erythematosus.